Category: Press Release - Page 47 - Psychedelic Alpha

Read more about the article HAVN Life Provides Corporate Update

HAVN Life Provides Corporate Update

Post published:September 21, 2022
Post category:Press Release

Read more about the article MindMed Collaborators Dose First Patient in Phase 1 Investigator-Initiated Trial of MDMA-Like Substances

MindMed Collaborators Dose First Patient in Phase 1 Investigator-Initiated Trial of MDMA-Like Substances

Post published:September 21, 2022
Post category:Press Release

Read more about the article COMPASS Pathways to participate in upcoming Jefferies Innovation in Mental Health Summit

COMPASS Pathways to participate in upcoming Jefferies Innovation in Mental Health Summit

Post published:September 21, 2022
Post category:Press Release

Read more about the article Bexson Biomedical Announces Renowned Scientist, Engineer and Inventor, Robert S. Langer ScD, Joins Its Scientific Advisory Board

Bexson Biomedical Announces Renowned Scientist, Engineer and Inventor, Robert S. Langer ScD, Joins Its Scientific Advisory Board

Post published:September 20, 2022
Post category:Press Release

Read more about the article Psyence Group Receives Phase IIa Clinical Trial Approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA)

Psyence Group Receives Phase IIa Clinical Trial Approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA)

Post published:September 19, 2022
Post category:Press Release

Read more about the article PsyBio Therapeutics Latest U.S. PCT (Non-Provisional) Patent Application Accepted

PsyBio Therapeutics Latest U.S. PCT (Non-Provisional) Patent Application Accepted

Post published:September 19, 2022
Post category:Press Release

Read more about the article Algernon Pharmaceuticals Files for Orphan Designation with the U.S. FDA for Ifenprodil as a Treatment of IPF

Algernon Pharmaceuticals Files for Orphan Designation with the U.S. FDA for Ifenprodil as a Treatment of IPF

Post published:September 19, 2022
Post category:Press Release

Read more about the article Small Pharma Completes Enrollment in Phase IIa DMT-Assisted Psychotherapy Clinical Trial in Patients With Major Depressive Disorder

Small Pharma Completes Enrollment in Phase IIa DMT-Assisted Psychotherapy Clinical Trial in Patients With Major Depressive Disorder

Post published:September 19, 2022
Post category:Press Release

Read more about the article Numinus Now Offers Ketamine-Assisted Therapy in Toronto

Numinus Now Offers Ketamine-Assisted Therapy in Toronto

Post published:September 19, 2022
Post category:Press Release

Read more about the article Clearmind Medicine Announces Share-Based Payment for one of the Company’s Consultants

Clearmind Medicine Announces Share-Based Payment for one of the Company’s Consultants

Post published:September 18, 2022
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.